Novel antibacterials targeting GyrA with increased selectivity and potency

Areas

Health

Fields of use

Healthcare-Medical Science

Current state of technology

Laboratory tested; preclinical studies in mice

Intellectual property

LU101131, patent pending

Developed by

University of Ljubljana, Faculty of Pharmacy and The National Institute of Chemistry

Reference

821-28/2018

Contact

Knowledge Transfer Office UL

Gabriela Droga Mazovec
Tel: +386 70 538 284
E-pošta: gospodarstvo@uni-lj.si

Download PDF

TO-Novel-antibacterials_EN.pdf (pdf, 389 KB)

Background

Antibiotic resistance is rising to dangerous levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. A growing list of infections – such as pneumonia, tuberculosis, blood poisoning, gonorrhoea, and foodborne diseases – are growing impossible to treat as antibiotics become less effective.

Description of invention

To address the problem we developed new compounds with novel monocyclic fragments coupled to an aminopiperidine naphthyridine moiety, comprising antibacterial activity. These compounds can be used for treating bacterial infections, including those provoked by antibiotic-resistant bacteria.

Main advantages

Antibiotic resistance leads to higher medical costs, prolonged hospital stays, and increased mortality. These new compounds offer a promising solution to the problem.